http://www.twitter.comTwitter is a service for friends, family, and co-workers to communicate and stay connected through the exchange of quick, frequent answers to one simple question: What are you doing?
View Older Stories View More Recent Stories
-
CytoSorbents Enrolls First Patient in TISORB Trial and Opens Operating Subsidiary in the United Kingdom
-
CytoSorbents to Report Q3 2019 Operating and Financial Results
-
CytoSorbents Awarded Approximately $3.0 Million by the U.S. Air Force to Advance Development of the K+ontrol System to Treat Severe Hyperkalemia
-
CytoSorbents to Present at The MicroCap Rodeo Investor Conference
-
Cytosorbents (CTSO) will present data from new study on cost effectiveness of CytoSorb when used intraoperatively to remove ticagrelor in patients undergoing emergency open heart surgery
-
CytoSorb® Removal of Ticagrelor Intraoperatively Results in Projected Cost Savings of Approximately $5,000 in Each Patient Undergoing Emergency Cardiac Surgery
-
CytoSorbents Announces Positive Surgical Outcomes From CytoSorb Removal Of Antithrombotics In Emergency Cardiothoracic Surgery
-
CytoSorbents Highlights Survival Benefit of CytoSorb Therapy in Septic Shock
-
First Study to Evaluate CytoSorb in Cytokine Release Syndrome (CRS) Following CAR T-cell Immunotherapy to Commence
-
World Sepsis Day 2019: CytoSorbents Highlights Its Support of Multiple Organizations In the Fight Against Sepsis
-
CytoSorbents to Present at the H.C. Wainwright 21st Annual Global Investment Conference
-
CytoSorbents Highlights Recent Published Studies on CytoSorb
-
CytoSorbents Receives Renewal of CytoSorb® CE Mark Through May 2024 and Annual ISO 13485:2016 Certification Through September 2022
-
CytoSorbents Expands CytoSorb Distribution in Latin America to Brazil, Colombia, and Costa Rica
-
CytoSorbents Reports Record Second Quarter 2019 Financial Results
-
CytoSorbents Announces Amendment to Loan Agreement with Bridge Bank, Receives an Additional $5 Million Cash from New Term Loan
-
CytoSorbents to Report Q2 2019 Operating and Financial Results
-
CytoSorbents to Present at the Raymond James Life Sciences and MedTech Conference
-
CytoSorbents to Present at the Three Part Advisors 2019 East Coast IDEAS Investor Conference
-
CytoSorbents to Present at the Jefferies 2019 Global Healthcare Conference
-
CytoSorbents to Participate at the B. Riley FBR 20th Annual Institutional Investor Conference
-
CytoSorbents Reports First Quarter 2019 Financial Results and Provides Second Quarter 2019 Guidance
-
CytoSorbents to Report Q1 2019 Operating and Financial Results
-
CytoSorbents Highlights the 6th International CytoSorb Users' Meeting and Recent Activities at the 2019 ISICEM and EuroELSO Conferences
-
CytoSorbents to Present at the H.C. Wainwright Global Life Sciences Conference 2019 London
-
Israel Approves CytoSorb Registration, CytoSorbents Announces Gad Medical as Distributor
-
CytoSorbents Achieves Record Revenue and Product Sales Growth in 2018
-
CytoSorbents to Present at the Cowen 39th Annual Health Care Conference
-
CytoSorbents Expands Direct Sales to Poland, the Nordics, and the Netherlands
-
CytoSorbents to Report Fiscal 2018 Operating and Financial Results
-
CytoSorbents to Participate at the 8th Annual SVB Leerink Global Healthcare Conference
-
CytoSorbents to Present at the 21st Annual BIO CEO & Investor Conference
-
Cytosorbents (CTSO) Announces DSMB Recommends Continuation of REMOVE Endocarditis Trial
-
CytoSorbents Announces the Data Safety Monitoring Board Recommends Continuation of REMOVE Endocarditis Trial
-
CytoSorbents Announces Expansion of CytoSorb® Partnership with Fresenius Medical Care
-
CytoSorbents Issues Stockholder Letter with Preliminary 2018 Financial Results
-
CytoSorbents To Highlight Progress at Biotech Showcase 2019
-
CytoSorbents To Receive $619,546 in Non-Dilutive Funding from the New Jersey Technology Business Tax Certificate Transfer Program
-
CytoSorbents to Present at the 30th Annual Piper Jaffray Healthcare Conference
-
CytoSorbents Recognized Again as One of the Fastest Growing Companies in North America on Deloitte's 2018 Technology Fast 500™
-
CytoSorbents to Present at the Stifel, Jefferies, and Canaccord Investor Conferences This Week
-
CytoSorbents Reports Third Quarter 2018 Financial Results
-
CytoSorbents to Report Q3 2018 Operating and Financial Results
-
CytoSorbents to Showcase CytoSorb® at Two Key European Medical Conferences
-
CytoSorbents to Present at the Cantor Fitzgerald Global Healthcare Conference
-
CytoSorb® Assigned Dedicated Procedure Code in Switzerland
-
World Sepsis Day 2018: CytoSorbents Sponsors the Sepsis Heroes Gala and the Roger Bone Award for Excellence in Sepsis Research
-
Cytosorbents (CTSO) Reports FDA Approval for REFRESH 2-AKI Protocol Amendment
-
CytoSorbents REFRESH 2-AKI Protocol Amendment Approved by FDA
-
CytoSorbents to Present at the B. Riley FBR Healthcare Conference and the H.C. Wainwright 20th Annual Global Investment Conference

